CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

cangrelor

Trade name: kengreal

Small moleculeapproved

Approved

Jun 22, 2015

Cangrelor is a P2Y12 inhibitor that has been approved as an antiplatelet drug. It is marketed in the US under the brand name Kengreal and in Europe as Kengrexal. Cangrelor is an intravenous, direct-acting reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention. — NCATS

Clinical trial activity

29 trials · 30 clinical orgs · 4 marketing orgs

Phase 1
3
Phase 2
11
Phase 3
4
Phase 4
13

Earliest trial started Mar 1, 2005 (NCT00102674)

Timeline

2000s

  1. Jan 1, 2005

    The Medicines Company — Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2006

    The Medicines Company — Earliest Phase 3 Sponsor(trial)

  3. Jan 1, 2008

    The Medicines Company — Earliest Phase 2 Sponsor(trial)

2010s

  1. Jun 22, 2015

    The Medicines Company — Earliest FDA Approval

  2. Jun 22, 2015

    Chiesi — Marketing Organization

  3. Jun 22, 2015

    The Medicines Company — NDA Organization

  4. Jun 22, 2015

    Chiesi — NDA Secondary Org

2020s

  1. Aug 11, 2025

    Gland Pharma Ltd — Marketing Organization

  2. Jun 4, 2026

    MSN Laboratories — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedJun 22, 2015

Chemistry & pharmacology

Loading structure…

SMILES

CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)[C@@H](O)[C@H]1O
Mol. weight
776.37 g/mol
Lipinski Ro5
3 violation(s)
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • ar c69931mx
  • ar-c69931mx
  • ar-c69931mx
  • ar-c69931mx
  • ar-c69931mx
  • ar-c69931xx
  • ar-c69931xx
  • ar-c69931xx
  • arl69931
  • canegrelor
  • canegrelor
  • canegrelor
  • canegrelor
  • canegrelor
  • cangrelor
  • cangrelor
  • cangrelor
  • cangrelor
  • cangrelor
  • cangrelor
  • cangrelor
  • cangrelor
  • cangrelor
  • cangrelor
  • cangrelor
  • cangrelor tetrasodium
  • cangrelor tetrasodium
  • cangrelor tetrasodium
  • cangrelor tetrasodium
  • [dichloro-[[[(2r,3s,4r,5r)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid
  • [dichloro-[[[(2r,3s,4r,5r)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid
  • kengreal
  • kengreal
  • kengreal
  • kengreal
  • kengrexal
  • n(6)-(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)-5'-adenylic acid monoanhydride with dichloromethylenebis(phosphonic acid)

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07225842Phase 4Nov 25, 2025University of Florida
NCT06792643Phase 2Apr 1, 2024Vita-Salute University of Milano. Italy
NCT06089577Phase 4Oct 31, 2023University of Naples Frederico II
NCT04667078Phase 3Sep 15, 2021Adolphe Rothschild Ophtalmologic Foundation
NCT04927949Phase 4Jun 8, 2021Terumo Corporation, University of Caen-Normandie
NCT04634162Phase 4Jan 31, 2021Scott R MacKenzie Foundation, University of Florida
NCT04668144Phase 4Jan 1, 2021Scott R MacKenzie Foundation, University of Florida
NCT04005729Phase 4Jul 31, 2019Chiesi, University of Ljubljana
NCT03862651Phase 2Jun 1, 2019Ospedale Santa Croce-Carle Cuneo
NCT03551964Phase 4Aug 1, 2018Charles University, Teaching Hospital Královské Vinohrady (FNKV)
NCT03247738Phase 4Nov 20, 2017Chiesi, University of Florida
NCT03273075Phase 4Sep 30, 2017Medical University of Vienna
NCT03182855Phase 4Aug 1, 2017Aarhus University
NCT03102723Phase 2May 1, 2017Government of Singapore, Nanyang Technological University, National University of Singapore
NCT02978040Phase 4Apr 1, 2017University of Bern
NCT02765633Phase 1Jan 3, 2017Chiesi, Columbia University
NCT03043274N/AJan 1, 2017University of Kentucky
NCT02943369Phase 4Oct 1, 2016Aristotle University of Thessaloniki, University of Alexandroupolis, University of Athens
NCT02733341Phase 4Jul 1, 2016The Royal Wolverhampton NHS Trust
NCT01979445Phase 2Nov 1, 2013The Medicines Company, University of Vermont
Showing 20 of 29 trials
Page 1 / 2

Organizations

Research & Development (30)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
The Medicines CompanyFor profit9932005
University of FloridaAcademic/Hospital4412017
ChiesiFor profit3122017
University of VermontAcademic/Hospital3012013
Duke UniversityAcademic/Hospital2012006
Scott R MacKenzie FoundationAcademic/Hospital2012021
University of KentuckyAcademic/Hospital2122005
University of RochesterAcademic/Hospital2012006
Aarhus UniversityAcademic/Hospital1112017
Adolphe Rothschild Ophtalmologic FoundationAcademic/Hospital1112021
Aristotle University of ThessalonikiAcademic/Hospital1012016
Charles UniversityAcademic/Hospital1012018
Columbia UniversityAcademic/Hospital1012017
Government of SingaporeGovernment1112017
Icahn School of Medicine at Mount SinaiAcademic/Hospital1112007
Medical University of ViennaAcademic/Hospital1112017
Nanyang Technological UniversityAcademic/Hospital1012017
National University of SingaporeAcademic/Hospital1012017
Ospedale Santa Croce-Carle CuneoAcademic/Hospital1112019
ScrippsAcademic/Hospital1012008
30 organizations
Page 1 / 2

Marketing (5)

OrganizationOrg typeRelationshipDate
ChiesiFor profitMKTGJun 22, 2015
ChiesiFor profitNDA2Jun 22, 2015
Gland Pharma LtdFor profitMKTGAug 11, 2025
MSN LaboratoriesFor profitMKTGJun 4, 2026
The Medicines CompanyFor profitNDAJun 22, 2015